Company intelligence / Profile preview
Allodynic Therapeutics
North Miami, Florida, United Statesallodynic.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Allodynic Therapeutics has completed four investigator-initiated clinical trials for its naltrexone-acetaminophen combination (ALLOD-2/Nalceta) that have shown promising results in treating various pain conditions. The company is now launching a phase-2 clinical study for treating acute migraine, with a trial (NCT05685225) scheduled to start on January 31, 2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesDrug combinations
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Allodynic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allodynic Therapeutics.